**SOMALIA**

**CERVICAL CANCER PROFILE**

### Morbidity and Mortality

Crude cervical cancer incidence per 100 000 women (2020): 13.2

Age-standardized cervical cancer incidence per 100 000 women (2020): 25.1

Cumulative risk of cervical cancer, ages 0-74 (2020): 2.8%

Cervical cancer deaths (2019): 880

Cervical cancer mortality-to-incidence ratio (2020): 0.77

Population-based cancer registry exists (2021): No

### Primary Prevention

**HPV vaccination programme coverage among girls (2020)**

<table>
<thead>
<tr>
<th>Programme coverage *</th>
<th>Coverage by age 15 †</th>
</tr>
</thead>
<tbody>
<tr>
<td>no data</td>
<td>no data</td>
</tr>
</tbody>
</table>

HPV vaccination is not included in the national vaccination schedule

**HPV vaccination programme (2020):**

HPV included in national vaccination programme: No

Scale of vaccination programme: -

Year of introduction: -

Primary target cohort: -

**Related risk factors:**

Tobacco use prevalence, women aged 15+ years (2020): ND

Condom use at last high-risk sex (-): ND

HIV incidence per 1000, women aged 15+ years (2020): 0.02

### Secondary Prevention

National screening programme for cervical cancer exists (2021): No

Primary screening test used (2021): -

Target age range of programme (2021): -

Programme/guidelines exist to strengthen early detection of first symptoms at primary health care level (2021): No

Clearly defined referral system exists from primary care to secondary and tertiary care (2021): No

### Treatment and Supportive Care

National guidelines on cervical cancer management exist (2021): No

**Cancer diagnosis and treatment services generally available (2021):**

- Cancer centre or cancer department at tertiary level: No
- Pathology services (laboratories): No
- Cancer surgery: No
- Chemotherapy: No
- Radiotherapy: No

**Palliative care for patients with NCDs in the public health system generally available (2021):**

- In primary health care facilities: No
- In community or home-based care: No

### WHO Cervical Cancer Elimination Strategy Targets for 2030

- 90% of girls fully vaccinated with the HPV vaccine by the age of 15
- 70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age
- 90% of women identified with cervical disease receive treatment

**ND = data not available**

* Programme coverage: % of national target population (among 9-14-year-old girls)
† Coverage by age 15: % of population turning 15 that have been vaccinated against HPV at any time between ages 9 to 14

See Explanatory Notes for indicator descriptions.